RxDoctor Payments Data

Guy Burrows, MD

Neurology · Shenandoah, TXNPI 1821075060

Payments from drug & device makers

$2,939in general payments, 2019–2025

Across 107 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols USA, LLC$1K
  • AbbVie$311
  • Takeda Pharmaceuticals U.S.A., Inc.$161
  • Biogen$161
  • Argenx US, Inc.$138
  • AstraZeneca$128
  • plus $816 from 20 others

What the payments were for

  • Food & beverage$2,87898%
  • Education$612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,939 in reported general payments places this provider in the 50th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$17,272,576
Medicare patients
175
Services billed
367,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 46341$3,760,015
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5070$1,976,784
GammakedImmune Globul G/Gly/Iga Avg 4637$729,667
PanzygaImmun Glob G(Igg)-Ifas/Glycine40$589,925
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5050$388,463
XywavSodium,calcium,mag,pot Oxybate12$240,097
Gabapentin125$3,253
Duloxetine Hcl90$1,967
Pregabalin62$1,705
Hydroxychloroquine Sulfate98$1,563
Tramadol Hcl60$714
Pyridostigmine Bromide12$671
Testosterone Cypionate37$633
Sodium Chloride0.9 % Sodium Chloride51$434
Clonazepam66$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$1,224$3,760,015341 claims
Bio Products Laboratory USA, Inc.Gammaplex$18$1,976,78470 claims
Kedrion Biopharma, Inc.Gammaked$16$729,66737 claims
PfizerPanzyga$46$589,92540 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$161$388,46350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,246 neurology providers in Texas.

Other neurology in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →